



Curriculum Vitae - Investigator and Site Staff

Statement of Education and Qualifications

PLEASE COMPLETE THE FOLLOWING INFORMATION:

Name (First, Middle, Last)	Academic Qualification(s) (e.g. MD, MBBS, Medical License Number, etc.)
Arijit Nag	M.B.B.S,M.D, D.M.,M.R.C.P Medical License Number: 65673

Current employment (Name of Institution, Street, City, Postal Code, State or Province (if applicable), Country)
Tata Medical center, 14, MAR (E-W), Newtown, Rajarhat, kolkata- 700160, WB

Work Telephone Number (Country Code, Area Code, Number)	Work Email Address
+91-9051121161	arijit.nag@tmckolkata.com drarijitnag@gmail.com

Education and Training (List all Colleges, Universities and Medical Schools attended, postdoctoral/fellowship training, board certification/medical license. Add more rows as needed)

Name and Location of Institution (City, State or Province and Country)	Degree and Year Awarded (Date format: ddMmmyyyy)	Area of Study
NRS Medical College, Kolkata, West Bengal, India	MBBS, Aug 2004 to April 2010	-
Institute of Post-Graduate Medical Education and Research, Kolkata, West Bengal, India	MD, June 2011 to May,2014	Internal Medicine
Institute of Hematology and Transfusion Medicine, Medical College and Hospitals, Kolkata, West Bengal, India	DM, Aug 2014 to July 2017	Clinical Hematology
Royal College of Physicians, UK	MRCP, 2017	-
Tata Medical Center, Kolkata, West Bengal, India	Post- Doctoral Fellowship in Hematology and Bone Marrow Transplantation, Sep 2018 to March 2019	-
University of Toronto	Clinical Fellowship in Allogenic Stem cell transplant April 2019 to June 2020	-

Professional Experience (include current position first, then list previous positions in reverse date order. Please add rows as needed.)

Position/Title	Name and Location of Institution (City, State or Province and Country)	Dates (Start/Stop Dates as applicable. ddMmmyyyy)
Consultant (Rank of Associate Professor)	Department of Clinical Hematology and Cellular Therapy, Tata Medical Center, Kolkata, West Bengal, India	July 2022 to Present
Consultant (Rank of Associate Professor)	Department of Clinical Hematology and Cellular Therapy, Tata Medical Center, Kolkata, West Bengal, India	July 2020 to July 2022

Form No.: CS_FM_RSU0035 Revision 4
Effective Date: 15May2023

Reference: CS_WI_RSU0021

Copyright © 2017, 2018, 2021, 2023 IQVIA. All rights reserved. The contents of this document are confidential and proprietary to IQVIA Holdings Inc. and its subsidiaries. Unauthorized use, disclosure or reproduction is strictly prohibited.

Curriculum Vitae - Investigator and Site Staff

Clinical Fellow	Allogenic BMT Program, Department of Hematology and Medical Oncology, Princess Margaret Cancer Center, University of Toronto	April 2019 to June 2020
Senior Fellow	Department of Clinical Hematology and Cellular Therapy, Tata Medical Center, Kolkata, West Bengal, India	Sep 2018 to March 2019
Associate Consultant	Department of Hematology, Medical College, Kolkata	Sep 2017 to Sep 2018
Senior Resident	Department of Hematology, Medical College, Kolkata	Aug 2014 to July 2017
Junior Resident	Institute of Post-Graduation Medical Education and Research, Kolkata, West Bengal, India	June 2011- May 2014

Previous participation in clinical trials (please add rows as needed)

Indication of Trial	Clinical Phase of Trial (I-IV)	Role in Trial (e.g. Investigator, Sub-Investigator)	Year trial was conducted
CML & Ph+ ALL	II	Sub-Investigator	2020
MDS & CMML-2	III	PI	2021
TATA PRECISION ONCOLOGY PROJECT- ALTITUDE STUDY	Observational / Analytical	Sub-Investigator	2020
CLL/ Mantle Cell Lymphoma	IV	PI	2021
CLL/ Mantle Cell Lymphoma	IV	Sub-Investigator	2021
MDS & Symptomatic Anemia	II	PI	2024
High risk Large B-cell Lymphoma	III	PI	2025
Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, Post essential thrombocythemia Myelofibrosis with severe thrombocytopenia	III	PI	2024
Multiple Myeloma	II	Sub-Investigator	2021
Relapsed Advanced Lymphoma	I	Sub-Investigator	2025
RRMM	I/II	Sub-Investigator	2025
MM	III	Sub-Investigator	2024
Relapsed Advanced Malignancies	I	Sub-Investigator	2024
RRMM	II	Sub-Investigator	2024
RRMM	IV	Sub-Investigator	2025

Form No.: CS_FM_RSU0035 Revision 4
Effective Date: 15May2023

Reference: CS_WI_RSU0021

Copyright © 2017, 2018, 2021, 2023 IQVIA. All rights reserved. The contents of this document are confidential and proprietary to IQVIA Holdings Inc. and its subsidiaries. Unauthorized use, disclosure or reproduction is strictly prohibited.



Curriculum Vitae - Investigator and Site Staff

Current Training on ICH/GCP (International Conference on Harmonisation, Good Clinical Practice).

Please provide, for your most current training, the type of training and year training was completed (or provide a copy of the certificate with this document). If you have not had training, please state "none" in the box below. Please add rows as needed

24 September, 2025

Other Evidence of Experience or Expertise

List other documents evidencing experience or expertise below and attach to this document. If no other documents, please state "none" in the box below. Please add rows as needed.

Peer reviewed manuscripts : Hematology focus

1. CORTES, J. E., KIM, D.-W., SAIKIA, T., KHATTRY, N., RATHNAM, K., ALVARADO, Y., HANNAH, G., TANTRAVAH, S. K., APPERLEY, J. F. & CHARBONNIER, A. 2025. Vodobatinib for patients with Philadelphia chromosome-positive chronic myeloid leukaemia resistant or intolerant to multiple lines of previous therapy: an open-label, multicentre, phase 1/2 trial. *The Lancet Haematology*.
 2. Nag A, Radhakrishnan VS, Kumar J, Bhav S, Mishra DK, Nair R, Chandy M. Thalidomide in Patients with Transfusion-Dependent E-Beta Thalassemia Refractory to Hydroxyurea: A Single-Center Experience. *Indian J Hematol Blood Transfus*. 2020 Apr;36(2):399-402. doi: 10.1007/s12288-020-01263-2. Epub 2020 Mar 2. PubMed PMID: 32425398; PubMed Central PMCID: PMC7229140.
 3. Biswas S, Nag A, Ghosh K, Ray R, Roy K, Bandyopadhyay A, Bhattacharyya M. Genetic determinants related to pharmacological induction of foetal haemoglobin in transfusion-dependent HbE- β thalassaemia. *Ann Hematol*. 2019 Feb;98(2):289-299. doi: 10.1007/s00277-018-3536-x. Epub 2018 Nov 9. PubMed PMID: 30413899.
 4. Nag A, Ghosh S, Sinha D, Mondal S, Roy SS, Ghosh A, Bhattacharyya M. Ultrasonography of Knee Joint in Hemophilia A: What the Eyes Cannot See. *Indian J Hematol Blood Transfus*. 2019 Jan;35(1):149-154. doi: 10.1007/s12288-018-0974-5. Epub 2018 Jun 18. PubMed PMID: 30828163; PubMed Central PMCID: PMC6369076.
 5. Nag A, Bhattacharyya M. Rivaroxaban Induced Thrombocytosis: A Perplexing Clinical Challenge. *Indian J Hematol Blood Transfus*. 2018 Oct;34(4):772-773. doi: 10.1007/s12288-018-0935-z. Epub 2018 Mar 5. PubMed PMID: 30369764; PubMed Central PMCID: PMC6186222.
 6. Sinha S, Chatterjee SS, Biswas M, Nag A, Banerjee D, De R, Sengupta A. SWI/SNF subunit expression heterogeneity in human aplastic anemia stem/progenitors. *Exp Hematol*. 2018 Jun;62:39-44.e2. doi: 10.1016/j.exphem.2018.03.005. Epub 2018 Mar 27. PubMed PMID: 29596882.
 7. Vs R, D P, H M, P M, R A, S S, D D, I A, Z L, N A, A N, J K, R J, S j B, M P, D k M, M C, R N. Primary Central Nervous System Lymphoma: Long-Term Treatment Outcomes and Cost-Analysis from a Retrospective Study of High-Dose Methotrexate Based Chemoimmunotherapy and Reduced Dose Radiation Therapy Approach. *Indian J Hematol Blood Transfus*. 2022 Apr;38(2):223-234. doi: 10.1007/s12288-021-01444-7. Epub 2021 May 18. PubMed PMID: 35496970; PubMed Central PMCID: PMC9001787.
-
1. Radhakrishnan VS, Bajaj R, Raina V, Kumar J, Bhav S, Sukumaran Nair RK, Nag A, Arun I, Zameer L, Dey D, Arora N, Parihar M, Das J, Achari RB, Mishra DK, Chandy M, Nair R. Relapsed Refractory Hodgkin Lymphoma and Brentuximab Vedotin-Bendamustine Combination Therapy as a Bridge to Transplantation: Real-World Evidence From a Middle-Income Setting and Literature Review. *Front Oncol*. 2021;11:796270. doi: 10.3389/fonc.2021.796270. eCollection 2021. PubMed PMID: 35127505; PubMed Central PMCID: PMC8814627.
 2. Pincha R, Radhakrishnan V, Kumar J, Nag A, Bhav S, Zameer L, Vinarkar S, Das J, Mishra D, Chandy M. Refractory Primary Mediastinal B-Cell Lymphoma: A Case Report of Conventional Chemotherapies, Immune Checkpoint Inhibitors, Polatuzumab Vedotin, Transplantation, and Post-Transplant Large Granular Lymphocytosis. *Indian Journal of Medical and Paediatric Oncology*. 2022.
 3. Javed R, Roychowdhury M, Bhav S, Nag A, Kumar J, Radhakrishnan V, Bhattacharya S, Mishra D, Ghara N, RS R. Impact of COVID-19 on peripheral stem cell collection and preservation at a hematopoietic cell transplant center in India: Experience 2020. *Blood Cell Ther*. 2021; 4:84-87.
 4. Shaw J, Chakraborty A, Nag A, Chattopadhyay A, Dasgupta AK, Bhattacharyya M. Intracellular iron overload leading to DNA damage of lymphocytes and immune dysfunction in thalassemia major patients. *Eur J Haematol*. 2017 Nov;99(5):399-408. doi: 10.1111/ejh.12936. Epub 2017 Sep 13. PubMed PMID: 28815805.

Form No.: CS_FM_RSU0035 Revision 4
Effective Date: 15May2023

Reference: CS_WI_RSU0021

Curriculum Vitae - Investigator and Site Staff

Peer reviewed manuscripts : Non Hematology focus

1. Nag A, Datta J, Das A, Agarwal AK, Sinha D, Mondal S, Ete T, Chakraborty A, Ghosh S. Acute kidney injury and dermonecrosis after *Loxosceles reclusa* envenomation. *Indian J Nephrol.* 2014 Jul;24(4):246-8. doi: 10.4103/0971-4065.133017. PubMed PMID: 25097339; PubMed Central PMCID: PMC4119339.
2. Arijit N, Sinha D, Mondal S, Chakraborty A, Ghosh A. Carpal tunnel syndrome as a presenting feature of polymyositis: a case report from India. *Archives of Rheumatology.* 2014; 29(3):224-227.
3. Sinha D, Mondal S, Nag A, Ghosh A. Development of a colour Doppler ultrasound scoring system in patients of Takayasu's arteritis and its correlation with clinical activity score (ITAS 2010). *Rheumatology (Oxford).* 2013 Dec;52(12):2196-202. doi: 10.1093/rheumatology/kev289. Epub 2013 Sep 6. PubMed PMID: 24014648.
4. Sinha D, Nag A, Mondal S, Ghosh A. AB0761 Comparison Between Colour Doppler Ultrasound and MRI in Documenting Response to Treatment with Nsaids and in Assessing Disease Activity in Non-Radiographic Spondyloarthritis. *BMJ Publishing Group Ltd;* 2015. 0003-4967.
5. Ghosh A, Mondal S, Sinha D, Nag A, Chakraborty S. Comment on: Ultrasonography as a useful modality for documenting sacroiliitis in radiographically negative inflammatory back pain: a comparative evaluation with MRI: reply. *Rheumatology (Oxford).* 2015 Aug;54(8):1535. doi: 10.1093/rheumatology/kev127. Epub 2015 Jun 3. PubMed PMID: 26044043.
6. Sinha D, Nag A, Mondal S, Ghosh a. Comparison between colour doppler ultrasound and mri in documenting response to treatment with nsaids and in assessing disease activity in non-radiographic spondyloarthritis. *Annals of the rheumatic diseases.* 2015; 74:1153-1153.
7. Sinha D, Mondal S, Nag A, Lahiri D, Ghosh A. Clinical and doppler monitoring of patients with Takayasu arteritis with ITAS 2010 and CDUS-K score respectively following medical intervention: a 12 months follow-up study. *International Journal of Research in Medical Sciences.* 2018; 6(11):3602.
8. Mondal S, Sinha D, Nag A, Chakraborty A, Ete T, Ghosh A. Sterno clavicular joint osteoarthritis in a patient with rheumatoid arthritis a case report with Classical sonographic features. *Journal of Diagnostic Medical Sonography.* 2015; 31(3):186-189.
9. Mondal S, Sinha D, Nag A, Chakraborty A, Ete T, Ghosh A. Sterno clavicular joint osteoarthritis in a patient with rheumatoid arthritis a case report with Classical sonographic features. *Journal of Diagnostic Medical Sonography.* 2015; 31(3):186-189.

Book chapters and other publications

Lam W, Nag A, Kumar R. Outcomes of Bone Marrow Transplantation. *Contemporary Bone Marrow Transplantation.* 2020; :1-43.

Meeting abstracts

Nag A, Roychowdhury M, Garg J, Bhav S, Chaudhuri S, Nair R, Mallath M, Chandy M. Profile of acute graft-versus-host-disease of the gastrointestinal tract following allogeneic haematopoietic cell transplantation from a tertiary care centre in India. *BONE MARROW TRANSPLANTATION.* 2019; 54:329-330.

Radhakrishnan V, Tamboli N, Das S, Garg J, Nag A, Bhav S, Parihar M, Vinarkar S, Mukhopadhyay S, Chakraborty S. Bortezomib-Pomalidomide-Dexamethasone (VPD) As Novel Induction Therapy in Newly-Diagnosed Multiple Myeloma: Early Safety Data from an Ongoing Single Arm Phase-II Investigator-Initiated Clinical Trial (PRIME Study). *Blood.* 2021; 138:2752.

Radhakrishnan V, Pattnaik S, Bhadhuri A, Raina V, Mandal P, Bhav S, Garg J, Nag A, Vinarkar S, Parihar M. Induction Mortality in Acute Myeloid Leukemia: A 9 Year Retrospective Study from a Tertiary Care Centre in a Low-Middle Income Country Setting. *Blood.* 2021; 138:4388.

Cortes J, Saikia T, Kim D, Alvarado Y, Nicolini F, Rathnam K, Khattry N, Apperley J, Deininger M, de Lavallade H. An Update of Safety and Efficacy Results from Phase 1 Dose-Escalation and Expansion Study of Vobociclib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI), in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Failing Prior TKI Therapies. *Blood.* 2021; 138:309

Iqbal A, Nag A, Bhattacharyya M, Ray S, Choudhuri S. PS1184 ANALYSIS OF BCR-ABL1 TRANSCRIPT LEVELS AT 3 MONTHS IN PREDICTING OVERALL RESPONSE IN PATIENTS OF CHRONIC MYELOID LEUKEMIA-CHRONIC PHASE ON 1ST LINE THERAPY WITH IMATINIB MESYLATE. *HemaSphere.* 2019; 3(S1):539.



Curriculum Vitae - Investigator and Site Staff

Iqbal A, Nag A, Bhattacharyya M, Ray S, Choudhuri S. PB1925 COMPARATIVE STUDY OF GLIVEC VERSUS STATE SPONSORED GENERIC IMATINIB MESYLATE AS FIRST LINE THERAPY IN CHRONIC MYELOID LEUKEMIA-CHRONIC PHASE. HemaSphere. 2019; 3(S1):875.

Javed R, Roychowdhury M, Bhav S, Kumar J, Krishnan S, Nag A, Mishra D, Bhattacharya S, Ks R, Ghara N. HALF-TRUTH: GRAFT CRYOPRESERVATION DOES NOT IMPACT ENGRAFTMENT AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT (ALLO-HCT)-A SINGLE CENTER EXPERIENCE FROM INDIA. CYTOTHERAPY. 2022; 24(5):S99-S99.

Tamboli N, Nag A, Radhakrishnan V, Kumar J, Bhav S, Javed R, Bhattacharya S, Goel G, Chatterji S, Mukherjee S. Outcome of sars-cov2 infection in hematological disorders: A tertiary-care cancer center experience. Indian Journal of Hematology and Blood Transfusion. 2020; :S121-S122.

Salas M, Atenafu E, Nag A, Bascom O, Wilson L, Lam W, Law A, Pasic I, Al-Shaibani Z, Kim D. Prospective Pilot Study on Frailty and Function Assessment During Clinics in Allogeneic Hematopoietic Cell Transplantation. BONE MARROW TRANSPLANTATION. 2020; 55(SUPPL 1):144-145.

Signature

Date (ddMmmmyyyy)

Anju Nag

25-09-2025